RAPT Therapeutics Files 8-K Report
| Field | Detail |
|---|---|
| Company | Rapt Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Oct 23, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $30.00, $28.20, $234.4 m, $269.7 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
RAPT filed an 8-K on 10/23 for events on 10/21. Standard update.
AI Summary
On October 21, 2025, RAPT Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events detailed in the provided excerpt. The report was filed on October 23, 2025.
Why It Matters
This 8-K filing indicates RAPT Therapeutics is providing updates or submitting required financial information to the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report with no immediately apparent negative or positive material events disclosed in the provided text.
Key Numbers
- 001-38997 — SEC File Number (Identifies the company's filing with the SEC)
- 47-3313701 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- RAPT Therapeutics, Inc. (company) — Registrant
- October 21, 2025 (date) — Earliest event reported
- October 23, 2025 (date) — Date of report filing
- 561 Eccles Avenue, South San Francisco, CA 94080 (location) — Principal Executive Offices
FAQ
What specific "Other Events" are being reported by RAPT Therapeutics in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" beyond listing the item category.
What is the significance of the "Financial Statements and Exhibits" being listed as an item in this 8-K?
This indicates that the company is either filing updated financial statements or including exhibits as part of this report, as required or voluntarily.
When was RAPT Therapeutics, Inc. incorporated or jurisdiction of incorporation?
RAPT Therapeutics, Inc. is incorporated in Delaware.
What was RAPT Therapeutics, Inc.'s former company name?
The former company name was FLX Bio, Inc., with a date of name change on May 4, 2016.
What is the business address and phone number for RAPT Therapeutics, Inc.?
The business address is 561 Eccles Avenue, South San Francisco, CA 94080, and the phone number is (650) 489-9000.
Filing Stats: 1,138 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2025-10-23 08:00:26
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share RAPT The Nasdaq
- $30.00 — price to the public in the Offering is $30.00 per share of Common Stock, and the Unde
- $28.20 — he Underwriting Agreement at a price of $28.20 per share. Under the terms of the Under
- $234.4 m — from the Offering will be approximately $234.4 million, or approximately $269.7 million
- $269.7 million — mately $234.4 million, or approximately $269.7 million if the Underwriters exercise in full th
Filing Documents
- rapt-20251021.htm (8-K) — 52KB
- rapt-ex1_1.htm (EX-1.1) — 336KB
- rapt-ex5_1.htm (EX-5.1) — 20KB
- 0001193125-25-247715.txt ( ) — 571KB
- rapt-20251021.xsd (EX-101.SCH) — 24KB
- rapt-20251021_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. Underwritten Public Offering On October 21, 2025, RAPT Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC, TD Securities (USA) LLC, Guggenheim Securities, LLC, Wells Fargo Securities, LLC and LifeSci Capital LLC, as representatives of the several underwriters set forth therein (collectively, the "Underwriters"), relating to the public offering, issuance and sale of 8,333,334 shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), in an underwritten public offering (the "Offering"). The price to the public in the Offering is $30.00 per share of Common Stock, and the Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $28.20 per share. Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option, exercisable for 30 days from the date thereof, to purchase up to an additional 1,250,000 shares of Common Stock. The Company estimates that the net proceeds from the Offering will be approximately $234.4 million, or approximately $269.7 million if the Underwriters exercise in full their option to purchase additional shares of Common Stock, in each case after deducting underwriting discounts and commissions and estimated Offering-related expenses. Based on the Company's current operating plans, the Company estimates the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities, will be sufficient for the Company to fund its operations into 2028. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could deplete its capital resources sooner than it currently expects. The closing of the Offering is expected to occur on October 23, 2025, subject to customary closing conditions. The Underwriting Agreement contains customary representations, warranties
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated October 21, 2025 . 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RAPT Therapeutics, Inc. Date: October 23, 2025 By: /s/ Rodney Young Rodney Young Chief Financial Officer